The PI3K/AKT Pathway As a Target for Cancer Treatment

Overview

Journal Annu Rev Med

Publisher Annual Reviews

Specialty General Medicine

Date 2015 Oct 17

PMID 26473415

Citations 396

Authors

Ingrid A Mayer

Carlos L Arteaga

Affiliations

Soon will be listed here.

Abstract

Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

Citing Articles

Dietary Restrictions and Cancer Prevention: State of the Art.

Caprara G, Pallavi R, Sanyal S, Pelicci P Nutrients. 2025; 17(3).

PMID: 39940361 PMC: 11820753. DOI: 10.3390/nu17030503.

mTOR Inhibitor Everolimus Modulates Tumor Growth in Small-Cell Carcinoma of the Ovary, Hypercalcemic Type and Augments the Drug Sensitivity of Cancer Cells to Cisplatin.

Zheng K, Gao Y, Xu J, Kang M, Chai R, Jin G Biomedicines. 2025; 13(1).

PMID: 39857585 PMC: 11759183. DOI: 10.3390/biomedicines13010001.

Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine.

Yang X, Yang D, Qi X, Luo X, Zhang G Front Oncol. 2025; 14():1467033.

PMID: 39845328 PMC: 11753220. DOI: 10.3389/fonc.2024.1467033.

Metabolic interplays between the tumour and the host shape the tumour macroenvironment.

Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A Nat Rev Cancer. 2025; .

PMID: 39833533 DOI: 10.1038/s41568-024-00786-4.

Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy.

Gan M, Liu N, Li W, Chen M, Bai Z, Liu D Mol Cancer. 2024; 23(1):273.

PMID: 39696340 PMC: 11657557. DOI: 10.1186/s12943-024-02193-7.